Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

Teva Pharmaceuticals

Status and phase

Completed

Phase 2

Conditions

Asthma

Treatments

Drug: Nebulized IVX-0142

Study type

Interventional

Funder types

Industry

Identifiers

NCT00232999

IXR-201-04-142

Details and patient eligibility

About

This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.

Enrollment

15 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Mild stable allergic asthma
Positive skin-prick test to at least one common aeroallergen
Positive methacholine challenge
Positive allergen-induced early- and late-phase airway bronchoconstriction
General good health

Exclusion criteria

Lung diseases other than mild allergic asthma
History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease
Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium
Use of tobacco products within one year starting study or smoking history >10 pack years
If female, pregnant or lactating or have positive pregnancy test at screening